Life sciences technology firm Rapid Micro's Q4 preliminary revenue rises

Rapid Micro Biosystems

13/01/2026 21:24

Overview

Life sciences tech firm's preliminary Q4 revenue up 37%, slightly beating analyst expectations

Company received record order from top biopharma client for global manufacturing automation

Preliminary full-year 2025 revenue grew 20%

Outlook

Rapid Micro Biosystems expects full-year 2025 revenue of approximately $33.6 mln

Company anticipates continued growth in 2026 supported by strategic partnerships

Result Drivers

RECORD ORDER - Co received record multi-system order from a top biopharma client for global manufacturing automation

SYSTEM PLACEMENTS - Placement of 16 new Growth Direct systems in Q4 contributed to revenue growth

Key Details

Metric
Beat/Miss
Actual
Consensus Estimate
Q4 Revenue
Slight Beat*
$11.30 mln
$11.20 mln (4 Analysts)

*Applies to a deviation of less than 1%; not applicable for per-share numbers.

Analyst Coverage

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"

Wall Street's median 12-month price target for Rapid Micro Biosystems Inc is $8.00, about 160.6% above its January 12 closing price of $3.07

Press Release: ID:nGNX6KPRbP

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)